Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original

The recent Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original.

These "follow-on" drugs are the latest trend for drug companies looking to replace drugs with expiring patents.

But these new versions usually don't offer much improvement.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote